A Novel Conformation of the ZIKV Protease Provides a Unique 3D Scaffold for Discovering Allosteric Protease Inhibitors as Direct Anti-virals, via HT and Virtual Screening, and Protein Engineering
A Novel Conformation of the ZIKV Protease Provides a Unique 3D Scaffold for Discovering Allosteric Protease Inhibitors as Direct Anti-virals, via HT and Virtual Screening, and Protein Engineering
批准号:
9757689
负责人:
SUMIT K CHANDA
金额:
$24.38万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-08-08 至 2020-07-31
关键词:
3-DimensionalActive SitesAcuteAdoptedAdultAedesAffinityAnimal TestingAntibodiesAntibody-Dependent EnhancementAntiviral AgentsBindingBiological AssayBrazilC-terminalCellsChronicCleaved cellClinicClinicalComplexComputer SimulationCrystallizationCulicidaeDengueDevelopmentDiseaseDistalDistantDrug KineticsDrug TargetingElementsEngineeringEnzymatic BiochemistryExhibitsFlaviviridaeFlavivirusFlavivirus InfectionsGenomeGuillain-Barré SyndromeHepatitis C virusHydrophobicityIn VitroIndividualInfectionJapanese encephalitis virusLibrariesLife Cycle StagesLigandsMembraneMicrocephalyMinorityMolecular ConformationN-terminalNatureNeurologicOutcomePathway interactionsPeptide HydrolasesPeptidesPersonsPolyproteinsPopulationPowder dose formProtease InhibitorProtein EngineeringProteinsRNA HelicaseReportingRiskSeminal fluidSexual TransmissionSpecificityStructureSurfaceSymptomsTemperatureTestingTherapeuticToxic effectVaccinesViralVirtual LibraryWest Nile virusWorkZIKV infectionZika Virusbasebiophysical techniquesconformercytotoxicitycytotoxicity testdesigndrug discoverydruggable targethuman pathogeninfection riskinhibitor/antagonistinnovationmeltingmutantneonatal infectionnovelpathogenpreferenceprenatalscaffoldscreeningsmall moleculesmall molecule therapeuticssuccesstherapeutic developmentvaccine developmentvirtual
中文摘要
项目摘要
寨卡病毒黄病毒(ZIKV)是一种在全球和美国出现的新病原体。寨卡病毒感染通常会导致轻微
症状;然而,ZIKVBR感染在一些人中导致了严重的神经后遗症,
包括成人的格林-巴利综合征和产前感染的婴儿的小头畸形。没有任何治疗方法
黄病毒感染是可以获得的。DENV黄病毒的疫苗策略一直令人失望,可能是因为
对抗体依赖的感染增强(ADE);已证明抗体对
DENV导致ZIKV的ADE。此外,ZIKV在精液中处于非常高的水平长达六个月
感染后。由于只有约20%的感染者表现出明显的感染迹象,性行为的风险
传输率大大提高。这些问题突出了治疗性小分子方法的必要性。
直接针对病毒生命周期的病毒。黄病毒NS2B-NS3蛋白是裂解多蛋白所必需的
具有病毒感染性,是一个有吸引力的目标。这项建议的主要创新之处在于我们最近
ZIKV NS2B-NS3新的“第三”构象蛋白酶的结晶学观察
“双开”状态。它与“封闭”和“单一开放”的国家不同,因为它进行了彻底的重组
NS3PRO的C末端底物结合的β-发夹与蛋白酶活性不相容。这双倍的-
打开状态显示一个新的表面暴露的深疏水口袋,位于活性部位的远端,它出现
高度可毒品,因为它在黄病毒中高度保守,并与重组的β-
发夹。因此,紧密结合在这个口袋上的小分子应该会稳定这种不活跃的状态,并起到
变构抑制剂。我们建议从真实图书馆和虚拟图书馆开始检验这一假设。原则上,
与活性部位的抑制剂相比,变构抑制剂应该具有更强的特异性,因为许多宿主
蛋白水解酶具有非常相似或相同的目标识别序列。我们进一步假设我们独一无二的
支架应该通过产生共晶结构来提供精制抑制HITS的更好的途径
指导进一步设计,这是开发更传统变构的一个问题
以不稳定的NS2B-NS3界面上的浅口袋为靶点的抑制剂。我们新奇口袋的本质应该是
加速共结晶。我们将使用传统的HT方法和
在硅胶筛查中进行袖珍指导。最初的筛选是PTS,突变的蛋白水解酶被锁定在“双-
打开“状态。小分子口袋粘结剂应提高熔融温度。宿主蛋白水解酶与
目标首选项将用作计数器屏幕。存活的HITS对蛋白酶的抑制将使用
羟色胺荧光肽筛选。将使用HepaRG细胞测试细胞毒性,并使用Huh-7.5细胞进行抑制
感染ZIKV巴西毒株。我们将使用生物物理技术验证变构结合,co-
结晶和酶学;通过共结晶优化直接缓蚀剂。我们期待着获得
~5种适合于进一步开发治疗的抑制剂。
英文摘要
Project Summary
Zika flavivirus (ZIKV) is an emerging pathogen globally and in the US. ZIKV infection usually causes mild
symptoms; however, ZIKVBR infection has in some individuals resulted in serious neurological sequelae,
including Guillain-Barré syndrome in adults, and microcephaly in prenatally-infected infants. No treatments for
flaviviral infections are available. Vaccine strategies for DENV flavivirus have been disappointing, possibly due
to Antibody-Dependent Enhancement of infection (ADE); and it has been demonstrated that antibodies to
DENV result in ADE for ZIKV. Furthermore, ZIKV is present at very high levels in semen for up to six months
post-infection. Since only ~20% of infected persons exhibit visible signs of infection, the risk of sexual
transmission is greatly increased. These issues highlight the need for therapeutic small-molecule approaches
that directly target the viral life-cycle. The flaviviral NS2B-NS3 protease is required for polyprotein cleavage and
viral infectivity and represents an attractive target. The major innovation of this proposal arises from our recent
crystallographic observation of a novel “third” conformation of ZIKV NS2B-NS3 protease, which we call the
“double-open” state. It is distinguished from the “closed” and “single-open” states by a radical reorganization
of the C-terminal substrate-binding β-hairpin of NS3PRO that is incompatible with protease activity. This double-
open state displays a new surface-exposed, deep hydrophobic pocket, distal to the active site, which appears
highly druggable, since it is highly conserved among flaviviruses, and lined with elements of the reorganized β-
hairpin. Thus, small molecules that bind tightly to this pocket should stabilize this inactive state, and act as
allosteric inhibitors. We propose to test this hypothesis starting with both real and virtual libraries. In principle,
allosteric inhibitors should have much greater specificity compared with active-site inhibitors, since many host
proteases have very similar, or identical target recognition sequences. We further hypothesize that our unique
scaffold should provide a superior pathway to refinement of inhibitory hits by generating co-crystal structures to
guide further design, an element that has been problematic for the development of more conventional allosteric
inhibitors that target shallow pockets at the labile NS2B-NS3 interface. The nature of our novel pocket should
expedite co-crystallization. We will screen compound libraries using both conventional HT approaches and
pocket-directed in silico screening. The primary screen is PTS, with mutant protease locked into the “double-
open” state. Small-molecule pocket binders should raise the melting temperature. Host proteases with similar
target preferences will be used as counter-screens. Protease inhibition by surviving hits will be tested using a
HT fluorescent peptide screen. HepaRG cells will be used to test for cytotoxicity and Huh-7.5 cells for inhibition
of infection by ZIKV Brazil strain. We will validate allosteric binding using biophysical techniques, co-
crystallization and enzymology; and direct inhibitor optimization by co-crystallization. We anticipate obtaining
~5 inhibitors suitable for further therapeutic development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Determinants of HIV-1 innate immune sensing and its role in shaping the lymphoid environment.
-
批准号:10712594
-
项目类别:
-
资助金额:$92.25万
-
财政年份:2023
-
负责人:SUMIT K CHANDA
-
依托单位:
Administrative Core
-
批准号:10514318
-
项目类别:
-
资助金额:$678.15万
-
财政年份:2022
-
负责人:SUMIT K CHANDA
-
依托单位:
Center for Antiviral Medicines & Pandemic Preparedness (CAMPP)
-
批准号:10514317
-
项目类别:
-
资助金额:$6762.42万
-
财政年份:2022
-
负责人:SUMIT K CHANDA
-
依托单位:
Reversing Immune Dysfunction for HIV-1 Eradication
-
批准号:10469447
-
项目类别:
-
资助金额:$498.68万
-
财政年份:2021
-
负责人:SUMIT K CHANDA
-
依托单位:
Reversing Immune Dysfunction for HIV-1 Eradication
-
批准号:10313784
-
项目类别:
-
资助金额:$500.18万
-
财政年份:2021
-
负责人:SUMIT K CHANDA
-
依托单位:
Reversing Immune Dysfunction for HIV-1 Eradication
-
批准号:10540209
-
项目类别:
-
资助金额:$498.45万
-
财政年份:2021
-
负责人:SUMIT K CHANDA
-
依托单位:
Project 2 - Host-virus networks regulating flu replication and host responses ex vivo
-
批准号:10080715
-
项目类别:
-
资助金额:$56.88万
-
财政年份:2018
-
负责人:SUMIT K CHANDA
-
依托单位:
Early development of small molecule dendritic cell immunopotentiators for the treatment of solid tumors
-
批准号:10180915
-
项目类别:
-
资助金额:$37.1万
-
财政年份:2018
-
负责人:SUMIT K CHANDA
-
依托单位:
Project 2 - Host-virus networks regulating flu replication and host responses ex vivo
-
批准号:10322693
-
项目类别:
-
资助金额:$19.5万
-
财政年份:2018
-
负责人:SUMIT K CHANDA
-
依托单位:
Project 2 - Host-virus networks regulating flu replication and host responses ex vivo
-
批准号:10322687
-
项目类别:
-
资助金额:$45.05万
-
财政年份:2018
-
负责人:SUMIT K CHANDA
-
依托单位:
Innate Immune Surveillance of HIV-1 During Transmission and Systemic Infection
-
批准号:9345240
-
项目类别:
-
资助金额:$91.01万
-
财政年份:2017
-
负责人:SUMIT K CHANDA
-
依托单位:
Innate Immune Surveillance of HIV-1 During Transmission and Systemic Infection
-
批准号:10541358
-
项目类别:
-
资助金额:$37.95万
-
财政年份:2017
-
负责人:SUMIT K CHANDA
-
依托单位:
Development of SMAC mimetics as latency-reversing agents
-
批准号:9300858
-
项目类别:
-
资助金额:$66.4万
-
财政年份:2016
-
负责人:SUMIT K CHANDA
-
依托单位:
Development of SMAC mimetics as latency-reversing agents
-
批准号:9927593
-
项目类别:
-
资助金额:$66.4万
-
财政年份:2016
-
负责人:SUMIT K CHANDA
-
依托单位:
Regulators of Innate Immune Responses to Gamma-herpesviruses
-
批准号:8660812
-
项目类别:
-
资助金额:$43.9万
-
财政年份:2014
-
负责人:SUMIT K CHANDA
-
依托单位:
ISG CONTROL OF FLAVIVIRUS INFECTION
-
批准号:8601427
-
项目类别:
-
资助金额:$61.32万
-
财政年份:2013
-
负责人:SUMIT K CHANDA
-
依托单位:
ISG CONTROL OF FLAVIVIRUS INFECTION
-
批准号:8976143
-
项目类别:
-
资助金额:$59.23万
-
财政年份:2013
-
负责人:SUMIT K CHANDA
-
依托单位:
ISG CONTROL OF FLAVIVIRUS INFECTION
-
批准号:9188794
-
项目类别:
-
资助金额:$58.22万
-
财政年份:2013
-
负责人:SUMIT K CHANDA
-
依托单位:
ISG CONTROL OF FLAVIVIRUS INFECTION
-
批准号:8479609
-
项目类别:
-
资助金额:$61.07万
-
财政年份:2013
-
负责人:SUMIT K CHANDA
-
依托单位:
ISG CONTROL OF FLAVIVIRUS INFECTION
-
批准号:8787070
-
项目类别:
-
资助金额:$60.34万
-
财政年份:2013
-
负责人:SUMIT K CHANDA
-
依托单位:
海外基金